Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — Verastem Inc: Versus-7375 Demonstrates Robust Anti-tumor Activity Across Advanced Kras G12d-mutant Cancers, Highlighted By 50% Confirmed Orr In 2l Pancreatic Ductal Adenocarcinoma And Two Complete Responses In 2l+ Disease (One Confirmed) Verastem - To Open Target-d 301 1l Mpdac Trial By Year-end 2026
The company reports 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease.
For best results when printing this announcement, please click on link below: VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) VS-7375 900 mg QD mono